{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Investigational
Source:
NCT03681093: Phase 3 Interventional Completed Nasal Polyps
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Fevipiprant is a selective reversible antagonist of the prostaglandin D2 receptor (also known as CRTH2). It is currently in development for the treatment of allergic diseases.
Status:
Investigational
Source:
Antimicrob Agents Chemother. May 2022;66(5):e0139921.: Phase 3 Human clinical trial Completed Pneumonia, Ventilator-Associated
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04469998: Phase 2 Interventional Completed Posterior Blepharitis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
GW-870086 (now known as GSK 870086) was developed by GlaxoSmithKline as a glucocorticoid receptor agonist. Repeat inhaled doses of GW-870086 was studied in phase II clinical trial in patients with asthma. In addition, phase II clinical trial was investigated to determine the efficacy of GW-870086 ream formulation in subjects with moderate to severe atopic dermatitis. However, the development of this drug appears to have been discontinued.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Allocupreide is a copper(l) complex used as an antiinflammatory drug and antiarthritic agent. It was used for the treatment of trigeminal neuralgia.
Status:
Investigational
Source:
NCT03678116: Not Applicable Interventional Completed Energy Metabolism
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01970215: Phase 2 Interventional Completed Dyslipidemia
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01081782: Phase 2 Interventional Completed Multiple Sclerosis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ceralifimod (ONO-4641) is an oral, selective Sphingosine 1-phosphate receptor 1 and 5 agonist. It was studied in the phase 2 trials for the treatment of multiple sclerosis, however, further, development was discontinued.
Status:
Investigational
Source:
Eur Respir J. Jan 2004;23(1):76-81.: Not Applicable Human clinical trial Completed N/A
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01168479: Phase 3 Interventional Completed Prostate Cancer
(2009)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Imazapic is a selective herbicide for both the pre- and post-emergent control of some annual and perennial grasses and some broadleaf weeds.
Imazapic kills plants by inhibiting the production of branched chain amino acids, which are necessary for protein synthesis and cell growth. It has been useful for weed control in natural areas, particularly in conjunction with the establishment of native warm-season prairie grasses and certain legumes. Imazapic is relatively non-toxic to terrestrial and aquatic mammals, birds, and amphibians. It has a low level of toxicity to birds but is more toxic to aquatic life and honey bees. It has a high potential for bioaccumulation. Imazapic has an average half-life of 120 days in soil. It is may be persistent in soil systems but usually degrades quickly in aquatic systems via photolysis. It has a high aqueous solubility, is volatile and, based on its chemical properties, is moderately mobile and may leach to groundwater.
Status:
Investigational
Source:
NCT02723292: Not Applicable Interventional Completed Adolescent Problems
(2011)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
